Development and Validation of a Stromal Immune Phenotype Classifier for Predicting Immune Activity and Prognosis in Triple-Negative Breast Cancer
Development and Validation of a Stromal Immune Phenotype Classifier for Predicting Immune Activity and Prognosis in Triple-Negative Breast Cancer
复制标题
用于预测三阴性乳腺癌免疫活性和预后的基质免疫表型分类器的开发和验证
DOI：
10.1002/ijc.33009
复制
发表时间：
2020
影响因子：
6.4
通讯作者：
Xiaoming Xie
中科院分区：
文献类型：
--
作者：
Shaoquan Zheng;Yutian Zou;Xinhua Xie;Jie-ying Liang;Anli Yang;Kai Yu;Jian Wang;Hailin Tang;Xiaoming Xie
Our study aims to construct a prognosis‐related immune phenotype classifier for predicting clinical prognosis and immune activity in triple‐negative breast cancer (TNBC). A total of 237 patients with TNBC from Sun Yat‐sen University Cancer Center (SYSUCC) and 533 patients with TNBC from public datasets were included in our study. A stromal immune quantified index was generated with a LASSO Cox regression model based on five prognosis‐related immune cells evaluated by CIBERSORT or IHC and was used to determine immune phenotypes. Immune features were evaluated in the samples before chemotherapy. A total of 119 patients in the SYSUCC training cohort were classified into immune Phenotypes A and B according to the density of stromal CD4+ T cells, γδ T cells, monocytes, M1 macrophages and M2 macrophages. Phenotype A predicted better survival than Phenotype B, and the classification was further validated in the testing cohort of 118 patients and the validation cohort of 533 patients. In the combined cohort, significant differences were found in Phenotype A compared to Phenotype B for the 5‐year overall survival (83.5% vs 65.8%, respectively,P< .01) and the 5‐year disease‐free survival (87.3% vs 76.0%, respectively,P< .01). In Phenotype A, immune‐related pathways were significantly enriched, and a higher level of immune checkpoint molecules, including PD‐L1, PD‐1 and CTLA‐4, could be observed. The immune phenotype classification was an independent prognostic indicator for TNBC and might serve as a potential predictor for immune activity within the tumor microenvironment.
